EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bridging the gap: meta-epidemiological analysis on the clinical translation of stem cell-based therapies in women’s reproductive diseases

Hankun Su, Yu Jian, Ronghui Tang, Hoksan Chau, Xinyu Cheng, Xiao Liu, Yuqian Tong, Jinyao Ning, Xinhua Zhang, Jiayi Chen, Yilin Zhang, Zixin Tong und 5 weitere

Human Reproduction Open · 12.03.2026 · 2026 (2)

DOI: 10.1093/hropen/hoag024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction Open, online erschienen am 21.03.2026. Verfasst von Hankun Su und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Reproductive Medicine, Xiangya Hospital, Central South University, Changsha, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Program of Hunan Province, Youth Fund of Xiangya Hospital, Central South University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

STUDY QUESTION What is the current landscape of randomized controlled trials (RCTs) evaluating stem cell-based therapies for women’s reproductive diseases, and how effectively has preclinical research informed their clinical translation? SUMMARY ANSWER The current clinical trial landscape for stem cell-based therapies in women’s reproductive diseases is characterized by rapid growth in trial registration, particularly for premature ovarian failure (POF) and intrauterine adhesions (IUA), yet remains predominantly in early-phase, single-center, single-country studies with significant heterogeneity in design and outcome reporting. WHAT IS KNOWN ALREADY Stem cell-based therapies show promise in preclinical models for conditions such as POF, IUA, and endometriosis. However, despite increasing clinical interest, the extent to which these therapies have been rigorously evaluated in RCTs and how well clinical trials reflect preclinical evidence remains unclear. STUDY DESIGN, SIZE, DURATION This translational analysis integrated a meta-epidemiological approach with bibliometric methods. We searched the International Clinical Trials Registry Platform (ICTRP), ClinicalTrials.gov, EudraCT, and ChiCTR from inception to 1 December 2025, using terms related to ‘stem cells’, ‘reproductive diseases’, and ‘randomized controlled trials’. Only English and Chinese registration records were included. PARTICIPANTS/MATERIALS, SETTING, METHODS Two reviewers independently screened registration records for RCTs assessing stem cell or derivative therapies in women’s reproductive diseases. Eligible criteria included RCTs that reported the use of stem cells or their derivatives in female patients with reproductive conditions. Data on trial design, disease focus, stem cell type, source, phase, sample size, outcomes, and results were extracted. A hybrid approach combined traditional systematic data extraction with machine learning-assisted screening (ASReview) for basic research. Bibliometric analysis using VoSviewer and CiteSpace mapped research trends, while Health Research Classification System (HRCS) scores assessed translational potential. Consistency in screening and extraction was evaluated using kappa and Cronbach’s alpha. MAIN RESULTS AND THE ROLE OF CHANCE From 804 records, 38 RCTs met inclusion criteria. The majority were early-phase (Phase 1/2, 76.3%), single-center (81.6%), and conducted in one country (97.4%), with China (50.0%) and the USA (18.9%) leading. POF (34.2%), ovarian cancer (23.7%), and IUA (18.4%) were the most studied conditions. Umbilical cord-derived mesenchymal stem cells (28.9%) were the most commonly used. While preclinical research shows strong mechanistic support, especially for POF and IUA, there was minimal overlap in primary outcome measures across trials, limiting comparability. Only 36.8% of RCTs included safety as a co-primary endpoint, and 49% had short-term follow-up, raising concerns about long-term risks such as tumorigenicity. LIMITATIONS, REASONS FOR CAUTION The analysis may be subject to language bias (English and Chinese only), and some included trials were incomplete, relying on interim reports or press releases not peer-reviewed. The quality of individual RCTs was not formally assessed, and publication bias in basic research may influence bibliometric trends. WIDER IMPLICATIONS OF THE FINDINGS This study highlights a significant gap between robust preclinical evidence and fragmented clinical evaluation, with over-concentration on POF and underrepresentation of other high-potential conditions like endometriosis and thin endometrium. The findings underscore the need for international collaboration, standardized outcome sets, and harmonized regulatory frameworks to enable large-scale, high-quality trials that can translate regenerative potential into clinical reality. STUDY FUNDING/COMPETING INTEREST(S) This study was supported by the National Natural Science Foundation of China (82301835 and 82371682), the Science and Technology Program of Hunan Province (2024JJ4091 and 2023JJ40956), the Youth Fund of Xiangya Hospital, Central South University, China (2021Q03 and 2209090550121), the Postdoctoral Science Foundation of China (2022M713522 and 2021TQ0372), and the Innovation and Entrepreneurship Training Program for College Students (202510533012, S202410533307, and CXPY2025224). The authors declare no competing interests. REGISTRATION NUMBER https://doi.org/10.17605/OSF.IO/JM9EK.

Schlagwörter

Stichwörter der Autor:innen

clinical trialexosomemeta-epidemiological studypremature ovarian failurestem cellwomen’s reproductive diseases

Autor:innen und Institutionen

  • Department of Reproductive Medicine, Xiangya Hospital, Central South University, Changsha, China.
  • Clinical Research Center for Women's Reproductive Health in Hunan Province, Xiangya Hospital, Central South University, Changsha, China.
  • Department of Fetal Medicine, Xiangya Hospital, Central South University, Changsha, China.
  • Department of Obstetrics and Gynecology, Hunan University of Medicine General Hospital, Huaihua, China.

ORCID-Profile: Hui Li

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Program of Hunan Province
  • Youth Fund of Xiangya Hospital, Central South University
  • Postdoctoral Science Foundation of China
  • Innovation and Entrepreneurship Training Program for College Students

Zitieren

APA

Su, H., Jian, Y., Tang, R., Chau, H., Cheng, X., Liu, X., Tong, Y., Ning, J., Zhang, X., Chen, J., Zhang, Y., Tong, Z., Yang, Y., Zhao, Y., Sun, L., Chen, J., & Li, H. (2026). Bridging the gap: meta-epidemiological analysis on the clinical translation of stem cell-based therapies in women’s reproductive diseases. Human Reproduction Open, 2026(2). https://doi.org/10.1093/hropen/hoag024

Vancouver

Su H, Jian Y, Tang R, Chau H, Cheng X, Liu X, et al. Bridging the gap: meta-epidemiological analysis on the clinical translation of stem cell-based therapies in women’s reproductive diseases. Human Reproduction Open. 2026;2026(2). doi:10.1093/hropen/hoag024

BibTeX
@article{Su2026,
  author = {Su, Hankun and Jian, Yu and Tang, Ronghui and Chau, Hoksan and Cheng, Xinyu and Liu, Xiao and Tong, Yuqian and Ning, Jinyao and Zhang, Xinhua and Chen, Jiayi and Zhang, Yilin and Tong, Zixin and Yang, Yuemeng and Zhao, Yunyang and Sun, Liye and Chen, Jingjing and Li, Hui},
  title = {Bridging the gap: meta-epidemiological analysis on the clinical translation of stem cell-based therapies in women’s reproductive diseases},
  journal = {Human Reproduction Open},
  year = {2026},
  volume = {2026},
  number = {2},
  doi = {10.1093/hropen/hoag024}
}
Kostenlos starten →